All In Biotech

Drug Trial Radar · NCT06465368

A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause

AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO LETROZOLE ALONE IN POSTMENOPAUSAL WOMEN 18 YEARS OR OLDER WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER IN THE NEOADJUVANT SETTING

Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 121 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

121

Actual

Start

Jul 11, 2024

Primary completion

Jul 10, 2025

Study completion Jul 10, 2025

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jun 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the effects of the study medicine PF-07220060 plus letrozole, compared with the effects of taking letrozole alone without PF-07220060 for treatment of breast cancer. This study is seeking for participants who are: * women of age 18 years and older post menopause (either naturally or surgically). * confirmed to have Hormone receptor (HR) positive, Human epidermal growth factor receptor 2 (HER2) negative breast cancer. HER2 negative describes cells that have a small amount or none of a protein called HER2 on their surface. In normal cells, HER2 helps control cell growth. Cancer cells that are HER2 negative may grow more slowly and are less likely to recur (come back) or spread to other parts of the body than cancer cells that have a large amount of HER2 on their surface. * not been treated for their cancer before this study. Participants will be randomly assigned (like flipping a coin) to receive the treatment (PF-07220060 plus letrozole) or letrozole alone. Both PF-07220060 and letrozole are taken by mouth. PF-07220060 will be taken twice a day for 14 days. Letrozole will be taken once a day for 14 days. Participants will have a screening period for up to 28 days. If deemed fit, they will receive study treatment for 14 days, and then will have a follow-up visit about 28 days after their last dose. All participants will have at least one biopsy during the study. Biopsy is the removal of cells or tissues for examining. All participants will have a biopsy on Day 14. Additional assessments for safety including blood draws and interviews done by the site staff will be completed during the study.

Conditions

  • Breast Cancer

Interventions

  • PF-07220060Drug

    PF-07220060 given as tablet by mouth twice a day for 14 days.

  • letrozoleDrug

    Letrozole given as tablet by mouth once a day for 14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Complete Cell Cycle Arrest (CCCA) at Day 14Time frame: Day 14

Locations

51 sites in 13 countries. Site status is shown where the registry gives one.

  • Advocate Good Shepherd Hospital

    Barrington, Illinois

  • AMG -Crystal Lake

    Crystal Lake, Illinois

  • Advocate Lutheran General Hospital

    Park Ridge, Illinois

  • Advocate Medical Group

    Park Ridge, Illinois

  • Baylor College of Medicine Medical Center

    Houston, Texas

  • Baylor St. Luke's Medical Center

    Houston, Texas

  • Ben Taub General Hospital

    Houston, Texas

  • Harris Health System - Smith Clinic

    Houston, Texas

  • O'Quinn Medical Tower - McNair Campus

    Houston, Texas

  • START San Antonio

    San Antonio, Texas

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia

  • Royal Melbourne Hospital

    Parkville, Victoria, Australia

  • Institut Jules Bordet

    Anderlecht, Bruxelles-capitale, Région de, Belgium

  • UZ Leuven

    Leuven, Vlaams-brabant, Belgium

  • Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer

    Rennes, Ille-et-vilaine, France

  • Centre de Cancérologie du Grand Montpellier

    Montpellier, Languedoc-roussillon, France

  • Institut de Cancérologie de l'Ouest

    Saint-Herblain, Loire-atlantique, France

  • CHU de Saint-Etienne

    Saint Priest En Jarez, Pays de la Loire Region, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, Rhône, France

  • HCL, Centre Hospitalier Lyon Sud

    Saint-Genis-Laval, Rhône, France

  • Gustave Roussy

    Villejuif, Val-de-marne, France

  • CaritasKlinikum Saarbrücken St. Theresia

    Saarbrücken, Saarland, Germany

  • Ospedale Antonio Perrino

    Brindisi, Italy

  • Azienda Ospedaliero Universitaria Maggiore della Carità

    Novara, Italy

  • IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"

    Meldola, Emilia-Romagna, Italy

  • Fondazione IRCCS San Gerardo dei Tintori

    Monza, Lombardy, Italy

  • Azienda USL Toscana Nord Ovest_Ospedale Civile di Livorno

    Livorno, Tuscany, Italy

  • AIDPORT Sp. z o.o.

    Skórzewo, Greater Poland Voivodeship, Poland

  • Pratia MCM Krakow

    Krakow, Lesser Poland Voivodeship, Poland

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie

    Warsaw, Masovian Voivodeship, Poland

  • Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu

    Przemyśl, Podkarpackie Voivodeship, Poland

  • Narodny onkologicky ustav

    Bratislava, Slovakia

  • Nemocnica AGEL Komarno

    Komárno, Nitra Region, Slovakia

  • Seoul National University Hospital

    Seoul, Seoul-teukbyeolsi [seoul], South Korea

  • Hospital Universitario San Cecilio

    Granada, Spain

  • Hospital Universitario HM Sanchinarro

    Madrid, Spain

  • Hospital General Universitario de Elche

    Elche, Alicante, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, Barcelona [barcelona], Spain

  • Hospital Jerez de la Frontera

    Jerez de la Frontera, Cádiz, Spain

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Catalunya [cataluña], Spain

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.